Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Enterprise Products Partners logo

Enterprise Products Partners Cash Flow Statement

Operating, investing, and financing cash movements

Enterprise Products Partners generated $7.7B in operating cash flow over the trailing twelve months. After $5.5B in capital expenditures, free cash flow was $2.4B. Free cash flow decreased 0.4% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$7.7BNet Cash From Investing (TTM)-$4.8BNet Cash From Financing (TTM)-$3.0BCapital Expenditures (TTM)$5.5BNet Change In Cash (TTM)-$60.0M
Latest FilingQ1 2026
Report Date2026-05-07
Market Cap$79.6B
P/E Ratio13.49
ROE19.62%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Share of Profits (Losses) of Related Party$106M$94M$92M$90M$85M$76M
Other working capital changes—-$14M$21M-$14M$7M-$15M
Deferred income taxes$22M$11M$5M-$17M$47M$14M
Income (Loss) from Equity Method Investments$106M$94M$92M$90M$85M$76M
Income (Loss) from Equity Method Investments$106M$94M$92M$90M$85M$76M
Income (Loss) from Equity Method Investments$106M$94M$92M$90M$85M$76M
Net cash from operating activities$2.4B$2.3B$2.1B$1.7B$2.5B$1.5B
Net income$1.6B$1.4B$1.5B$1.4B$1.7B$1.5B
Amortization of capitalized software and acquired intangible assets$52M$52M$52M$55M$57M$58M
Amortization of major maintenance costs for reaction-based plants$17M$16M$15M$18M$23M$25M
Depreciation and Accretion$508M$511M$519M$531M$546M$555M
Distributions of earnings from equity method investees$103M$88M$101M$91M$84M$75M
Gain/(loss) on dispositions, net—$2M$7M$4M$1M-$1M
Equity in earnings (losses) of equity method investees$106M$94M$92M$90M$85M$76M
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital—-$203M—$322M—$861M
Operating lease right-of-use asset amortization$27M$28M$27M$27M$27M$28M
Other amortization expense$51M$57M$57M$56M$58M$63M
Impairment of assets and other charges$6M$10M$11M$17M$12M$8M
Unrealized Gain (Loss) on Derivatives and Commodity Contracts$9M-$42M$52M-$34M—-$98M
Income (Loss) from Equity Method Investments$106M$94M$92M$90M$85M$76M

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from Sales of Assets and Subsidiaries$3M$4M$11M$6M$61M$596M
Capital expenditures$1.1B$1.1B$1.3B$2B$1.3B$983M
Payment for (Proceeds from) Other Investing Activity$8M$4M$5M$4M$12M$5M
Proceeds from disposition of property, plant and equipment/other$3M$4M$11M$6M$61M$596M
Net cash from investing activities-$2B-$1B-$1.3B-$1.9B-$1.2B-$381M
Dividend Received from Consumer Healthcare JV$13M$15M$20M$21M$18M$11M
Proceeds from sale of PPE and intangibles$3M$4M$11M$6M$61M$596M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from minority shareholders$57M$4M$1M——$0
Distributions to noncontrolling interests$22M$13M$26M$29M$25M$23M
Cash payments made in connection with DERs$11M$11M$11M$11M$11M$11M
Distribution Made to Limited Partner, Cash Distributions Paid$1.1B$1.2B$1.2B$1.2B$1.2B$1.2B
Payments Of Debt Issuance Costs$0$12M$13M$4M$13M$4M
Proceeds from issuances of debt$1.3B$19.1B$30.5B$21.5B$17.2B$22.5B
Other, net$0-$80M-$5M-$3M—-$111M
Repayments of Debt$1.3B$19.4B$29.3B$20.6B$16.4B$23B
Net proceeds from sales of subsidiary shares$57M$4M$1M——$0
Payment of Deferred Purchase Consideration$0-$80M-$5M-$3M—-$111M
Noncontrolling interest transactions and other$0-$80M-$5M-$3M—-$111M
Proceeds from Minority Shareholders$57M$4M$1M——$0
Proceeds from Sale of Noncontrolling Interests$57M$4M$1M——$0
Net cash from financing activities-$1.2B-$1.7B-$145M-$467M-$424M-$1.9B
Noncontrolling Interests Activity and Other$0-$80M-$5M-$3M—-$111M
Proceeds from Minority Shareholders$57M$4M$1M——$0
Repurchases of common stock$63M$60M$110M$80M$50M$116M
Proceeds from Minority Shareholders$57M$4M$1M——$0

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$1.3B$1.3B$762M$0$1.2B$486M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net increase (decrease) in cash—-$384M$642M-$664M$813M-$851M